December 19, 2024

Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer

In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-fr...

The ASCO Post

December 09, 2024

Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit

Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data prese...

The ASCO Post

April 22, 2024

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

May 03, 2023

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–clau...

The ASCO Post

May 13, 2024

Oral Rinse Could Provide Early Screening for Gastric Cancer

A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented at Digestive Disease Week (DDW) 2024.

The ASCO Post

January 31, 2023

Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study

Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Fi...

The ASCO Post

December 21, 2023

Expert Point of View: Elizabeth Smyth, MD

Dr. Elizabeth Smyth from Oxford University Hospitals NHS Foundation Trust provides insights on the promising results and challenges of CMG901, a targeted antibody-drug conjugate, for advanced gastric or gastroesophageal junction cancer treatment.

The ASCO Post

February 13, 2023

Expert Point of View: David Wang, MD, PhD

Dr. David Wang discusses the significant survival benefit shown by zolbetuximab in the SPOTLIGHT trial for advanced gastric cancer, shedding light on its potential as a predictive biomarker.

The ASCO Post